This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Patel, V. Articles by Shrager, J. B. Search for Related Content PubMed PubMed Citation Articles by Patel, V. Articles by Shrager, J. B.

Which Patients with Stage III Non-Small Cell Lung Cancer Should Undergo Surgical Resection?

University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania

Correspondence: Joseph B. Shrager, M.D., Associate Professor of Surgery, General Thoracic Surgery, 4 Silverstein, HUP, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, USA. Telephone: 215-662-4767; Fax: 215-614-1861; e-mail: jshrag{at}mail.med.upenn.edu

The treatment of patients with stage III NSCLC remains controversial. Stage III NSCLC comprises a fairly heterogeneous group of tumors, and furthermore only sparse data from randomized clinical trials exist to guide therapy decisions. This review article proposes a management algorithm for patients with stage III NSCLC that is based upon the currently available data on surgical therapy, chemotherapy, and radiation therapy. By necessity, given the paucity of strong data, a good deal of opinion is offered. The choice to proceed with aggressive, combined modality treatment is presented in light of extent of local disease as well as patient performance status.

Key Words. Non-small cell lung carcinoma • Neoadjuvant therapy • Pulmonary surgical procedures • Neoplasm staging